These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 33445057)

  • 1. A novel mutation of walK confers vancomycin-intermediate resistance in methicillin-susceptible Staphylococcus aureus.
    Zhu J; Liu B; Shu X; Sun B
    Int J Med Microbiol; 2021 Feb; 311(2):151473. PubMed ID: 33445057
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A vancomycin resistance-associated WalK(S221P) mutation attenuates the virulence of vancomycin-intermediate Staphylococcus aureus.
    Rao Y; Peng H; Shang W; Hu Z; Yang Y; Tan L; Li M; Zhou R; Rao X
    J Adv Res; 2022 Sep; 40():167-178. PubMed ID: 36100324
    [TBL] [Abstract][Full Text] [Related]  

  • 3. WalK(S221P), a naturally occurring mutation, confers vancomycin resistance in VISA strain XN108.
    Peng H; Hu Q; Shang W; Yuan J; Zhang X; Liu H; Zheng Y; Hu Z; Yang Y; Tan L; Li S; Hu X; Li M; Rao X
    J Antimicrob Chemother; 2017 Apr; 72(4):1006-1013. PubMed ID: 27999059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evolution of multidrug resistance during Staphylococcus aureus infection involves mutation of the essential two component regulator WalKR.
    Howden BP; McEvoy CR; Allen DL; Chua K; Gao W; Harrison PF; Bell J; Coombs G; Bennett-Wood V; Porter JL; Robins-Browne R; Davies JK; Seemann T; Stinear TP
    PLoS Pathog; 2011 Nov; 7(11):e1002359. PubMed ID: 22102812
    [TBL] [Abstract][Full Text] [Related]  

  • 5. walK and clpP mutations confer reduced vancomycin susceptibility in Staphylococcus aureus.
    Shoji M; Cui L; Iizuka R; Komoto A; Neoh HM; Watanabe Y; Hishinuma T; Hiramatsu K
    Antimicrob Agents Chemother; 2011 Aug; 55(8):3870-81. PubMed ID: 21628539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complete Reconstitution of the Vancomycin-Intermediate Staphylococcus aureus Phenotype of Strain Mu50 in Vancomycin-Susceptible S. aureus.
    Katayama Y; Sekine M; Hishinuma T; Aiba Y; Hiramatsu K
    Antimicrob Agents Chemother; 2016 Jun; 60(6):3730-42. PubMed ID: 27067329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Investigating the effect of an identified mutation within a critical site of PAS domain of WalK protein in a vancomycin-intermediate resistant Staphylococcus aureus by computational approaches.
    Baseri N; Najar-Peerayeh S; Bakhshi B
    BMC Microbiol; 2021 Sep; 21(1):240. PubMed ID: 34474665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulating activity of vancomycin and daptomycin on the expression of autolysis cell-wall turnover and membrane charge genes in hVISA and VISA strains.
    Cafiso V; Bertuccio T; Spina D; Purrello S; Campanile F; Di Pietro C; Purrello M; Stefani S
    PLoS One; 2012; 7(1):e29573. PubMed ID: 22253738
    [TBL] [Abstract][Full Text] [Related]  

  • 9. VraR Binding to the Promoter Region of
    Dai Y; Chang W; Zhao C; Peng J; Xu L; Lu H; Zhou S; Ma X
    Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28289032
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Contribution of selected gene mutations to resistance in clinical isolates of vancomycin-intermediate Staphylococcus aureus.
    Hafer C; Lin Y; Kornblum J; Lowy FD; Uhlemann AC
    Antimicrob Agents Chemother; 2012 Nov; 56(11):5845-51. PubMed ID: 22948864
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comprehensive identification of mutations responsible for heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA)-to-VISA conversion in laboratory-generated VISA strains derived from hVISA clinical strain Mu3.
    Matsuo M; Cui L; Kim J; Hiramatsu K
    Antimicrob Agents Chemother; 2013 Dec; 57(12):5843-53. PubMed ID: 24018261
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacodynamic activity of ceftobiprole compared with vancomycin versus methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) using an in vitro model.
    Zhanel GG; Voth D; Nichol K; Karlowsky JA; Noreddin AM; Hoban DJ
    J Antimicrob Chemother; 2009 Aug; 64(2):364-9. PubMed ID: 19454524
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of an Amplicon Nanopore Sequencing Strategy for Detection of Mutations Conferring Intermediate Resistance to Vancomycin in Staphylococcus aureus Strains.
    Moller AG; Petit RA; Davis MH; Read TD
    Microbiol Spectr; 2023 Feb; 11(1):e0272822. PubMed ID: 36688645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cervimycin-Resistant Staphylococcus aureus Strains Display Vancomycin-Intermediate Resistant Phenotypes.
    Dietrich A; Steffens U; Gajdiss M; Boschert AL; Dröge JK; Szekat C; Sass P; Malik IT; Bornikoel J; Reinke L; Maček B; Franz-Wachtel M; Nieselt K; Harbig T; Scherlach K; Brötz-Oesterhelt H; Hertweck C; Sahl HG; Bierbaum G
    Microbiol Spectr; 2022 Oct; 10(5):e0256722. PubMed ID: 36173303
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emergence of vancomycin-intermediate and -resistant Staphylococcus aureus among methicillin-resistant S. aureus isolated from clinical specimens in the northwest of Iran.
    Ghahremani M; Jazani NH; Sharifi Y
    J Glob Antimicrob Resist; 2018 Sep; 14():4-9. PubMed ID: 29454049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic pathway in acquisition and loss of vancomycin resistance in a methicillin resistant Staphylococcus aureus (MRSA) strain of clonal type USA300.
    Gardete S; Kim C; Hartmann BM; Mwangi M; Roux CM; Dunman PM; Chambers HF; Tomasz A
    PLoS Pathog; 2012 Feb; 8(2):e1002505. PubMed ID: 22319446
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular Characterization of Methicillin and Vancomycin Resistant
    Jahanshahi A; Zeighami H; Haghi F
    Microb Drug Resist; 2018 Dec; 24(10):1529-1536. PubMed ID: 29883257
    [No Abstract]   [Full Text] [Related]  

  • 18. Mutated response regulator graR is responsible for phenotypic conversion of Staphylococcus aureus from heterogeneous vancomycin-intermediate resistance to vancomycin-intermediate resistance.
    Neoh HM; Cui L; Yuzawa H; Takeuchi F; Matsuo M; Hiramatsu K
    Antimicrob Agents Chemother; 2008 Jan; 52(1):45-53. PubMed ID: 17954695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exposure of Staphylococcus aureus to subinhibitory concentrations of β-lactam antibiotics induces heterogeneous vancomycin-intermediate Staphylococcus aureus.
    Roch M; Clair P; Renzoni A; Reverdy ME; Dauwalder O; Bes M; Martra A; Freydière AM; Laurent F; Reix P; Dumitrescu O; Vandenesch F
    Antimicrob Agents Chemother; 2014 Sep; 58(9):5306-14. PubMed ID: 24957836
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genomic analysis reveals a point mutation in the two-component sensor gene graS that leads to intermediate vancomycin resistance in clinical Staphylococcus aureus.
    Howden BP; Stinear TP; Allen DL; Johnson PD; Ward PB; Davies JK
    Antimicrob Agents Chemother; 2008 Oct; 52(10):3755-62. PubMed ID: 18644967
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.